Eterna Zentaris Reports First Quarter 2021 Financial Results And Provides Pipeline Program Updates News Today : Breaking News, Live Updates & Top Stories | Vimarsana

expected
beyond 2023
CHARLESTON, S.C., May 05, 2021 (GLOBE NEWSWIRE) AEterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna” or the “Company”), a specialty biopharmaceutical company developing and commercializing a diversified portfolio of pharmaceutical and diagnostic products, today reported its financial and operating results for the first quarter ended March 31, 2021. The Company also provided an update on its preclinical and clinical development programs.
“Over the course of the first quarter, we continued to execute on our key strategic priorities by significantly strengthening our balance sheet and expanding our development pipeline. This solid execution provides us with optionality to advance and accelerate our pipeline programs,” commented Dr. Klaus Paulini, Chief Executive Officer of Aeterna. ....

United Kingdom , Jenene Thomas , Klaus Paulini , Globe Newswire Aeterna Zentaris Inc , Novo Nordisk Biopharm Limited , Aeterna Zentaris , European Commission , University Of Queensland , University Of Sheffield , Queensland University , Aeterna Zentaris Inc , Vaccine Development Pipeline , Toronto Stock Exchange , European Union , Diagnostics Development Pipeline , Novo Nordisk , Research Agreement , Pivotal Phase , Chief Executive Officer , Clinical Programs Update , Vaccine Development , Clearance Parathyroid Hormone , Fusion Polypeptides , Underwriter Option , First Quarter , Financial Statements ,